Drugs / Anti-influenza IVIG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02037282 | Jan → Dec 2014 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-influenza IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02037282 ↗ |
| Known as | FLU-IVIG | “subjects will receive anti-influenza intravenous immunoglobulin (FLU-IVIG) and evaluated on Study Days 0, 3, 7, 14, and 28.” NCT02037282 ↗ |
| Modality | Protein / enzyme biologic | “anti-influenza intravenous immunoglobulin” NCT02037282 ↗ |
| Route | Intravenous | “anti-influenza hyperimmune intravenous immunoglobulin” NCT02037282 ↗ |